Bacon1

Jill Furmanovsky, the British rock photographer, has captured Oasis from their early days onwards—and her archive is a vivid visual chronicle of their rise, excesses, and inner dynamics. In a gallery of striking images, the article revisits that journey: from their breakthrough in 1994, through sweaty concerts and personal tensions, to Noel Gallagher reflecting on her influence. Furmanovsky describes how she sometimes felt like a “mother figure” to the band, navigating their unpredictable energy while preserving authenticity behind the camera. Noel praises her ability to get revealing, emotionally resonant shots without ego or interference. The photographs don’t just document performances—they show moments of vulnerability, creative intensity, and raw rock ‘n’ roll life. Through those frames, we see how the boundaries between art, trust, and chaos converged during Oasis’s peak years. Key Takeaways Jill Furmanovsky’s long collaboration with Oasis yielded iconic, candid images that reveal more than their stage presence. Her role extended beyond photographer—she sometimes acted as emotional ballast and trusted observer in the band’s stormy world. Noel Gallagher values her discreet but powerful presence; her work lets viewers “hear” moments captured in silence. Adapted From: https://www.theguardian.com/artanddesign/gallery/2025/sep/23/oasis-jill-furmanovsky-mad-for-it-in-pictures

Keir Starmer’s proposal to introduce mandatory digital ID cards in the UK has sparked fierce debate. The initiative, aimed at proving the right to work and tightening controls on illegal employment, has drawn both support and criticism from the public. Critics argue the system risks turning into mass surveillance, with sensitive data concentrated in one place – “a hacker’s dream,” as one IT consultant described it. Concerns over privacy, cybersecurity, and being forced into smartphone reliance were repeatedly raised, with some warning that it could exclude people who avoid constant digital engagement. Supporters counter that most European nations already operate similar systems, offering streamlined access to services such as healthcare and taxation. Some see digital IDs as a practical solution for managing personal records across multiple providers, easing burdens on families navigating health and welfare systems. The polarised reaction highlights the challenge of balancing efficiency and modernisation with safeguarding personal freedoms. While some believe digital IDs could help modernise public services, others view them as an unnecessary risk that places too much trust in government oversight. The debate reflects broader questions about data privacy, digital inclusion, and the role of technology in daily life. Whether the plan will gain acceptance or deepen public mistrust remains to be seen. Key Takeaways: Digital ID plan divides opinion over privacy, security, and surveillance risks. Supporters cite benefits such as faster access to services and record management. Critics warn of hacking risks, loss of privacy, and reliance on smartphones. Adapted From: https://www.theguardian.com/politics/2025/sep/27/britons-on-keir-starmer-plan-digital-id-cards

Conclusion from the above study.. "Oxidative stress, inflammation and acetaminophen exposure may interact to increase the risk of autism. While oxidative stress and inflammation have long been implicated in autism, acetaminophen exposure during critical periods of development may represent an important missing link.”

bickering comment removed @CallumWK

Unnecessary comment & reply removed @transam @BritManToo

Offensive comment & replies removed @Ralf001

Offensive post removed Replies removed @Ralf001 Forum Rules 8. You will not post vulgarities, obscenities or profanities.

Offensive post removed @dutch boy 15.You may not discriminate, use slurs, or post hostile or abusive comments based on personal characteristics such as race, gender, age, religion, ethnicity, nationality, disability, medical history, marital or family status, gender identity, or sexual orientation. Posts breaching this rule will be removed, and posting suspension or account closure may result.

Misleading post removed @Bday Prang Inappropriate meme removed @captain_shane Inappropriate post removed @Tim BKK Replies also removed

Overly rude comment removed. Please refrain from name calling of that calibre. @sammieuk1

Flame post removed & reply quote also removed. @TedG

@Tug Please provide a link. Failure to do so, will result in your post being removed. Thank you

Eli Lilly has discontinued a mid-stage clinical trial evaluating bimagrumab—an experimental drug intended to help obesity patients lose fat without sacrificing muscle mass—citing strategic business reasons. The trial, conducted in overweight or obese adults with type 2 diabetes, was testing bimagrumab alone and in combination with Lilly’s obesity drug tirzepatide (marketed under the brand name Zepbound). Originally designed to monitor not just total weight loss but specifically the balance between fat loss and muscle preservation, the study enrolled about 180 participants and ran for more than a year. The primary endpoint was weight reduction, while muscle versus fat retention was a safety concern. Lilly acquired bimagrumab through its ~$2 billion takeover of biotech firm Versanis. Analysts estimate that “muscle-safe” weight loss therapies could command over $30 billion in sales by 2035. Notably, Lilly ended the trial only weeks after its initiation (the study began earlier in June and was terminated June 10). However, a parallel study in obese patients without diabetes is still active, with results expected in 2026. Lilly said it routinely reviews its development pipeline to optimize each product’s potential. The company is among several racing to combine appetite-controlling GLP-1 drugs with complementary therapies that reduce muscle loss. Key Takeaways: Trial halted: Eli Lilly stopped testing bimagrumab in type 2 diabetes patients with obesity. Strategic shift: Decision follows a pipeline review, despite high market potential for muscle-preserving weight loss drugs. Ongoing research: A second trial in obese but non-diabetic patients continues, with results expected in 2026. Big market stakes: Analysts see fat-loss drugs that preserve muscle topping $30 billion in sales by 2035 Adapted From: https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-halts-trial-experimental-weight-loss-drug-2025-09-25/

British actor Noel Clarke was arrested at his family home in Kensington, London, following a police search of the property. Officers removed boxes—reportedly containing a laptop and documents—and Clarke was later held in custody for questioning before being released. The Metropolitan Police say the investigation began on 1 September and is being handled by its specialist crime command. They have declined to confirm whether the arrest is directly connected to the recent libel case Clarke lost against The Guardian, though some observers view that as a likely link. Clarke had challenged The Guardian over its 2021–22 investigation alleging misconduct by more than 20 women. In August, Mrs. Justice Steyn dismissed Clarke’s case, ruling The Guardian had successfully defended itself on grounds of truth and public interest. The judge also described Clarke as not entirely credible or reliable during proceedings. Clarke is 49 and gained recognition for his work in Doctor Who (playing Mickey Smith) and films like Star Trek Into Darkness and SAS: Rise of the Black Swan. He also wrote and produced Kidulthood and its sequels, and starred in the police-drama Bulletproof. Prior to the arrest, his BAFTA accolades—including the Rising Star award and Outstanding British Contribution honor—had been suspended following the allegations published in The Guardian. Details about the arrest’s precise cause remain undisclosed, and police have not stated whether formal charges will follow. Reporting continues as the case develops. Key Takeaways: Noel Clarke was arrested and questioned after a police raid on his London home. The arrest may relate to the libel case he recently lost against The Guardian. Clarke’s prior BAFTA honors have been suspended amid ongoing allegations and legal scrutiny. https://www.theguardian.com/uk-news/2025/sep/25/actor-noel-clarke-arrested-at-family-home-in-london

Bolivian police have arrested former anti-drug chief Felipe Cáceres after a cocaine laboratory was discovered on one of his properties. Cáceres, who led Bolivia’s Department for Controlled Substances from 2006 to 2019, oversaw the nation’s fight against narcotics for over a decade. His arrest marks another blow to Bolivia’s counternarcotics agencies, already shaken by past scandals involving senior officials accused of drug trafficking. Authorities said the lab was located in Puerto Villarroel, a key coca-growing region in Cochabamba. The facility was reportedly large enough to employ ten people and specialised in converting coca leaves into cocaine hydrochloride. Police detained Cáceres nearby, at a sand and gravel plant he owns. While the laboratory was found on land registered to him, officials have yet to confirm whether he directly operated or profited from it. Coca cultivation remains legal in Bolivia under strict regulation, with 22,000 hectares permitted for traditional, medicinal, and religious use. However, any production of cocaine is banned. Cáceres’s background as a former coca-growers’ union leader, combined with his subsequent government role, makes the case particularly high-profile. Interior Minister Roberto Ríos said investigations are ongoing to establish Cáceres’s level of involvement. Meanwhile, former President Evo Morales, a close ally of Cáceres during his tenure, denounced the arrest as a “set-up” intended to distract from current government controversies. Lawyers for Morales’s party stressed that prosecutors must prove a direct link between Cáceres and the illicit operation. Bolivia is the world’s third-largest producer of cocaine, after Colombia and Peru. The latest arrest highlights persistent challenges within the country’s efforts to combat narcotics, with previous top counternarcotics officials also facing charges abroad and at home. Key Takeaways: Former anti-drug czar Felipe Cáceres arrested after cocaine lab found on his land. Lab located in Bolivia’s coca-rich Cochabamba region, capable of employing ten workers. Arrest adds to ongoing scandals undermining Bolivia’s counternarcotics agencies. Adapted From: https://www.bbc.com/news/articles/crkj735r746o

It has been observed that one member has used the thumbs-down emoji excessively, with a total of 15 instances. These have been removed. @NickyLouie 11. You will not troll or stalk other members by misusing forum posts, private messages, reactions, emojis or by any other means.

An insensitive & inappropriate comment removed. @Cameroni

@rumak Post removed Be polite and respectful to other users

Hmmm..as long as it follows Forum Rules.

@Hummin @JakeC Multiple bickering posts removed. Shake hands, agree to disagree, stay on topic & stop bickering. 9. You will not post disruptive or inflammatory messages. You will respect other members and post in a civil manner. Personal attacks, insults or hate speech posted on the forum or sent by private message are not allowed.

The American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG) have strongly criticised recent White House announcements linking acetaminophen (Tylenol) use in pregnancy to autism and ADHD. The US Food and Drug Administration (FDA) said it would update acetaminophen’s label to note a potential association with neurodevelopmental conditions, citing studies such as the Nurses’ Health Study II and the Boston Birth Cohort. However, the agency itself acknowledged conflicting research and emphasised that a causal relationship has not been established. During the same announcement, the FDA also approved a label update for leucovorin, recognising it as a treatment for cerebral folate deficiency with autistic symptoms. This move was presented as a milestone by President Donald Trump and HHS Secretary Robert F. Kennedy Jr. The group stressed that autism is complex, with genetic and environmental factors at play, and reiterated that no credible research links vaccines to autism. ACOG echoed these concerns, cautioning that discouraging acetaminophen use could harm pregnant women who need fever relief, as untreated fever itself can pose risks to both mother and child. Experts noted that acetaminophen remains one of the most commonly used medications in pregnancy worldwide, valued for its safety profile when taken appropriately. Both AAP and ACOG emphasised the importance of clear, evidence-based communication to avoid fuelling confusion among parents. The debate underscores the tension between emerging scientific studies, political messaging, and the medical community’s call for caution in interpreting preliminary findings. Key Takeaways AAP and ACOG criticised White House claims linking acetaminophen to autism. FDA acknowledges conflicting evidence and says no causal link is proven. Experts stress the risks of discouraging safe medication use in pregnancy. Source adapted from: https://www.hcplive.com/view/acog-aap-respond-white-house-autism-announcements-acetaminophen-leucovorin?utm_source=chatgpt.com

@Simon 55 Simon, you have had multiple posts written in Hebrew. English is the only permitted language on AseanNow, apart from the Thai language sub-forum. If you have something you want to post & it's within the Forum Rules, then you must use English. 16. English is the only permitted language anywhere on ASEAN NOW, except within the Thai language forum, where using Thai is allowed. Short Thai translations of technical terms are permitted in specialty forums. While we make allowances for members who do not speak English as their first language, we expect everyone to make an effort to post in a manner that allows others to understand their posts. As an international forum we have members from many countries in the world, and English is not

Might I ask you, Khun Phoenix, what is your medical background?

In a landmark clinical trial, researchers in the UK report the first successful use of gene therapy to treat Huntington’s disease, showing a 75 % slowdown in disease progression over three years. The therapy works by delivering a modified, harmless virus into the brain to block production of the mutant huntingtin protein that kills neurons. The single-shot infusion, done over 12–20 hours via micro-catheter into two brain regions, was tested in 29 patients in the UK and US. The trial was led by Prof Sarah Tabrizi at UCL and marks a turning point for a disease long considered incurable. Early results show reductions in neurodegeneration markers (neurofilament levels) and improvements in motor, cognitive, and daily-life assessments among high-dose recipients. While the procedure is complex and costly, the outcome raises hope for wider treatment access and even preventative use in early-stage or presymptomatic carriers. Though full data have yet to be published, the company uniQure aims to file for regulatory approval next year. This breakthrough could shift the Huntington’s community’s approach to genetic testing—more people might opt in now that a therapy exists. That said, challenges remain: costs, surgical risks, long-term safety, and broader equity in access must be addressed before this becomes standard care. Key Takeaways Gene therapy in this trial reduced Huntington’s disease progression by ~75 % across motor, cognitive, and functional measures over 3 years. The treatment uses a viral vector to deliver DNA into neurons, shutting down the toxic mutant huntingtin protein. Barriers remain: cost, surgical complexity, long-term safety, and regulatory approval. Adapted From: https://www.theguardian.com/science/2025/sep/24/huntingtons-disease-treated-successfully-for-first-time-in-gene-therapy-trial Brief Explanation of HD. Huntington's disease (HD), also known as Huntington's chorea, is a neurodegenerative disease that is mostly inherited. It typically presents as a triad of progressive psychiatric, cognitive, and motor symptoms. The earliest symptoms are often subtle problems with mood or mental/psychiatric abilities, which precede the motor symptoms for many people.The definitive physical symptoms, including a general lack of coordination and an unsteady gait, eventually follow. Source: https://en.m.wikipedia.org/wiki/Huntington's_disease

A flotilla carrying humanitarian aid to Gaza was targeted by multiple drone attacks in international waters near Greece, according to organisers. Activists reported explosions, communication jamming, and drones dropping stun grenades on several vessels in the 50-boat convoy. No injuries were confirmed, though some boats sustained damage. Italian Prime Minister Giorgia Meloni condemned the attacks but also described the flotilla as “dangerous and irresponsible.” Italy has dispatched the naval frigate Fasan to support the convoy, which includes high-profile campaigners such as Greta Thunberg. Officials stressed that the vessel’s role is limited to assistance and potential rescue operations, not military engagement. The flotilla, part of the Global Sumud Flotilla initiative, set sail from Barcelona in late August to challenge Israel’s blockade of Gaza. Israel has accused the activists of aligning with Hamas, while participants insist their mission is non-violent and humanitarian. Videos posted online by activists show explosions near the boats, with one clip capturing a device hitting the mast of a sailing vessel. Italian Defence Minister Guido Crosetto condemned the attack, calling the perpetrators “unidentified.” Human rights campaigners on board, including activists from Germany, Brazil, and Italy, described witnessing more than a dozen drones approaching from multiple directions. This incident marks the third reported drone strike on the flotilla this month. Organisers vowed not to be deterred, stating: “We are witnessing psychological operations first-hand, but we will not be intimidated.” Key Takeaways: Gaza aid flotilla targeted by drone strikes; no injuries reported. Italy condemned the attacks but criticised the flotilla’s mission. Activists vow to continue despite repeated incidents this month. Adapted From: https://www.theguardian.com/world/2025/sep/24/explosions-and-multiple-drones-targeting-gaza-aid-flotilla-boats-activists-say